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Brief CommunicationAutocrine negative feedback regulation of
lipolysis through sensing of NEFAs by FFAR4/
GPR120 in WATAnna Sofie Husted 1, Jeppe H. Ekberg 1, Emma Tripp 2, Tinne A.D. Nissen 1, Stijn Meijnikman 3,
Shannon L. O’Brien 2, Trond Ulven 4,5, Yair Acherman 6, Sjoerd C. Bruin 6, Max Nieuwdorp 3,
Zach Gerhart-Hines 1, Davide Calebiro 2, Lars O. Dragsted 7, Thue W. Schwartz 1,*ABSTRACT
Objectives: Long-chain fatty acids (LCFAs) released from adipocytes inhibit lipolysis through an unclear mechanism. We hypothesized that the
LCFA receptor, FFAR4 (GPR120), which is highly expressed in adipocytes, may be involved in this feedback regulation.
Methods and results: Liquid chromatography mass spectrometry (LC-MS) analysis of conditioned media from isoproterenol-stimulated primary
cultures of murine and human adipocytes demonstrated that most of the released non-esterified free fatty acids (NEFAs) are known agonists for
FFAR4. In agreement with this, conditioned medium from isoproterenol-treated adipocytes stimulated signaling strongly in FFAR4 transfected
COS-7 cells as opposed to non-transfected control cells. In transfected 3T3-L1 cells, FFAR4 agonism stimulated Gi- and Go-mini G protein binding
more strongly than Gq, effects which were blocked by the selective FFAR4 antagonist AH7614. In primary cultures of murine white adipocytes, the
synthetic, selective FFAR4 agonist CpdA inhibited isoproterenol-induced intracellular cAMP accumulation in a manner similar to the antilipolytic
control agent nicotinic acid acting through another receptor, HCAR2. In vivo, oral gavage with the synthetic, specific FFAR4 agonist CpdB
decreased the level of circulating NEFAs in fasting lean mice to a similar degree as nicotinic acid. In agreement with the identified anti-lipolytic
effect of FFAR4, plasma NEFAs and glycerol were increased in FFAR4-deficient mice as compared to littermate controls despite having elevated
insulin levels, and cAMP accumulation in primary adipocyte cultures was augmented by treatment with the FFAR4 antagonist conceivably by
blocking the stimulatory tone of endogenous NEFAs on FFAR4.
Conclusions: In white adipocytes, FFAR4 functions as an NEFA-activated, autocrine, negative feedback regulator of lipolysis by decreasing
cAMP though Gi-mediated signaling.
 2020 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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For more than 40 years, nonesterified free fatty acids (NEFAs) have
been known to inhibit lipolysis, but the mechanism behind this inhi-
bition has remained unclear [1e3]. Initially, adenosine had been
described to function as an autocrine inhibitory regulator of lipolysis
[4]. However, in 1975, Fain and Shepherd reported that in dialyzed,
conditioned medium from isoproterenol-stimulated adipocytes, an
adenosine deaminase-resistant agent efficiently inhibited cAMP pro-
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www.molecularmetabolism.comexemplified by oleic acid [1]. It was concluded that the prolonged drop
in cAMP accumulation observed in adipocytes following treatment with
lipolytic agents was a result of liberated free fatty acids exceeding the
binding capacity of albumin in the medium and that fatty acids
apparently function as physiological feedback regulators of lipolysis
[1,2]. In 2012, by using chemically modified fatty acids, Kalderon et al.
demonstrated that the antilipolytic effect of NEFAs was independent of
their classical functions as metabolites, i.e., b-oxidation and re-
esterification [3]. Because key metabolites can act as extracellular
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Brief Communication(GPCRs) [5], the antilipolytic and cAMP-lowering effect of NEFAs in
adipocytes is most likely mediated through a long-chain fatty acid
(LCFA) receptor.
LCFAs are sensed by two GPCRs, FFAR1 (GPR40) and FFAR4 (GPR120)
[6,7]. Of these, FFAR1 is highly expressed in pancreatic and enter-
oendocrine cells [8,9], where it stimulates hormone secretion in
response to dietary, triglyceride-derived LCFAs [10,11]. In the
gastrointestinal (GI) tract, this occurs during the absorption process,
whereas in the pancreatic islet, FFAR1 most likely senses LCFAs that
are liberated locally from postprandial chylomicrons by lipoprotein
lipase [5,12]. FFAR1 is a Gq-coupled GPCR co-expressed with and
acting in synergy with the Gs-coupled GPR119 receptor, which is a
sensor of the other main triglyceride metabolite, 2-monoacyl glycerol
[10,13]. Recently, FFAR1 was shown to be responsible for a major part
of the glucose-induced insulin secretion through its function as an
autocrine sensor of 20-HETE, an arachidonic acid metabolite produced
in b-cells in response to glucose [14,15]. However, FFAR1 is very
poorly expressed in adipocytes and therefore likely not involved in the
autocrine sensing of NEFAs in adipocytes.
In contrast to FFAR1, FFAR4 is highly expressed in white and brown
adipose tissue (WAT and BAT) [16,17]. In WAT, FFAR4 has been re-
ported to be either upregulated or downregulated in response to high-
fat diet in mice and in obese patients [18e21]. However, in BAT,
FFAR4 expression is strongly upregulated upon cold exposure in mice
[3,16,22]. Although FFAR4 recognizes a broad spectrum of LCFAs, the
receptor is somewhat more sensitive to unsaturated fatty acids and
has accordingly been advocated to be responsible for the anti-
inflammatory and insulin-sensitizing effect of U-3 fatty acids [23].
However, it remains unclear whether the beneficial metabolic effects of
U-3 fatty acids are in fact mediated through FFAR4, as normal effects
of U-3 fatty acids have been reported in FFAR4-deficient mice [24,25].
Nevertheless, chronic treatment with an FFAR4 agonist has been
shown to improve insulin resistance and chronic inflammation in obese
mice [17,23].
Previously, we proposed that FFAR4, which is generally believed to be
a sensor of dietary unsaturated fatty acids may function as an auto-
crine sensor of NEFAs released from adipocytes and thereby act as a
feedback inhibitory brake on lipolysis [5]. This hypothesis was
experimentally tested in the present study.
2. EXPERIMENTAL PROCEDURES/MATERIAL AND METHODS
2.1. Compounds
Nicotinic acid and isoproterenol were purchased from SigmaeAldrich
(Steinheim, Germany). The FFAR4-selective agonists compound A
(CpdA) [23] and compound B (CpdB) [21] were provided by Merck (NJ,
USA), and AZ13581837 (AZ) [26] was synthesized by Chempartner
(Shanghai, China). The FFAR4-selective antagonist AH7614 [27] was
synthesized according to [28]. Chemical structures of each of the
FFAR4 ligands are shown in Fig. S1.
2.2. Mice
The C57BL/6J mice were purchased from Janvier Labs (France) at 8
weeks of age and either placed on a standard chow diet (Brogaarden,
Denmark) or a high-fat diet with a 60% fat content (Research Diets) for
24 weeks. The mice were group-housed with up to 8 mice per cage at
24 C on a 12:12 h lightedark cycle. The mice had free access to food
and water. The FFAR4KO and WT control mice were kindly provided by
Andy Howard, Merck (NJ, USA) and used for the experiment at 12
weeks of age. These mice were placed on a standard chow diet and
had free access to food and water. The studies were conducted in2 MOLECULAR METABOLISM 42 (2020) 101103  2020 The Authors. Published by Elsevier GmbH. Taccordance with institutional guidelines and approved by the Animal
Experiments Inspectorate under the Danish Ministry of Food, Agricul-
ture, and Fisheries. The mice were handled in a facility fully accredited
by the Association for Assessment and Accreditation of Laboratory
Animal Care.
2.3. Primary adipocyte cultures
Primary murine adipocytes were purified from epididymal fat pads
from lean C57BL6 mice. Samples of human adipocytes were obtained
during bariatric surgery of patients participating in the BARIA study
[29]. The study was performed in accordance with the Declaration of
Helsinki and was approved by the Academic Medical Center Ethics
Committee of the Amsterdam UMC. All participants provided written
informed consent. All individuals met the criteria for bariatric surgery
by the International Federation of Surgery for Obesity (IFSO) [30]. Three
adipose tissue compartments were analyzed in the present study, and
biopsies were obtained as follows: subcutaneous adipose tissue from
one of the laparoscopic incisions in the upper abdomen, mesenteric
adipose tissue from the appendices of the transverse colon, and
omental adipose tissue from the greater omental tissue as previously
described. Both the murine and human adipose tissues were washed
in phosphate-buffered saline (PBS), minced thoroughly into small
pieces, and transferred into a 50-ml tube with HEPES Krebs ringer
buffer (4% bovine serum albumin (BSA)) containing collagenase placed
in a water bath at 37 C with constant shaking for 1 h. The digested
cells were filtered and then allowed to stand for 5 min. The infranatant
was then carefully removed using a syringe with a long needle. Then,
the floating layer of adipocytes was washed 3 times with 10 ml of
HEPES Krebs ringer buffer (2% BSA). The adipocytes were resus-
pended in HEPES Krebs ringer buffer (2% BSA) supplemented with
glucose, phenylisopropyl adenosine (SigmaeAldrich), and adenosine
(Roche) and then plated in non-coated transparent 96-well plates and
stimulated with isoproterenol (1 mM) or vehicle for 30 min at 37 C.
NEFA content in the conditioned media was measured by a NEFA kit
from WAKO (WAKO Chemicals, Germany), and the content of LCFA was
determined by targeted liquid chromatography mass spectrometry (LC-
MS) analysis.
2.4. Targeted LC-MS analysis
Long-chain fatty acids were compared in the samples using the semi-
targeted metabolic profiling method previously described for plasma
samples (method II in [31]) with minor modifications; briefly, protein in
the samples was precipitated with 80% methanol:acetonitrile (50:50,
both chromatography grade from Fisher Chemicals, Leicestershire,
United Kingdom) and filtered on a 96-well Sirocco plate (Waters,
Taastrup, Denmark), and the filtrate was evaporated to dryness. The
samples were then redissolved in 96% ethanol, and 5 mL was injected
into a binary ultra-high-performance liquid chromatography (UHPLC)
system (Waters Acquity) equipped with an Acquity UPLC HSS T3
1.8 mm 2.1  100 mm column and eluted with a gradient going from
0.4 mL/min of 0.1% formic acid in water (A) to 1.2 mL/min of 100%
methanol (B) in 6.5 min and back to starting conditions for re-
equilibration from 7 min (the gradient is provided in the text for
Table S1). The detector was a QTof Premier (Waters) operating with a
capillary probe voltage at 2.8 kV in negative ionization mode (scan time
0.08 s; interscan delay 0.02 s; ion source temperature 120 C; des-
olvation gas temperature 400 C; cone voltage 30 kV; and cone and
desolvation gas flows 50 and 1,000 L/h, respectively). Leucine
enkephalin was infused every 10 s for 0.1 s as a lock-mass solution for
continuous mass calibration. Centroid data was generated in real time
and collected for masses ranging between 100 and 500 Da during allhis is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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runs. The RT and m/z of all fatty acid analytes are shown in Table S1,
as determined by external standards (0.5e50 ug/mL in 96% ethanol).
All samples were analyzed in the same batch together with assay
blanks (i.e., water processed as samples) and external standards to
assure no time drift or interfering background peaks during the
analysis. The resulting raw data were pre-processed using Markerlynx
software (Waters), and the extracted areas for each of the targeted
fatty acid peaks in all samples were used for statistical analysis. Assay
blanks contained no measurable fatty acid.
2.5. IP turnover assay
COS-7 cells were grown in Dulbecco’s modified Eagle’s medium (DMEM)
1885 supplemented with 10% fetal calf serum, 2 mM glutamine, 100
units/ml penicillin, and 100 mg/ml streptomycin. The cells were tran-
siently transfected with pCMV-Tag (2B) (Stratagene, Ca, USA) with or
without FFAR4 cDNA (short form) cloned into the vector in 96-well plates
(20,000 cells per well) using the calcium phosphate precipitation method
with chloroquine. Following transfection, the cells were incubated for 48 h
with 0.5 mCi/ml myo [3H]inositol (Perkin Elmer). After 48 h, cells were
washedwith Hanks Bovine Salt Solution (HBSS, Gibco, Life Technologies)
and incubated for 2 h at 37 C in 100 ml of HBSS supplemented with
10mMof LiCl together with either conditionedmedia from the adipocytes,
CpdA, CpdB, AZ compound, or vehicle control media. The cells were lysed
with 40ml of cold 10mM formic acid on ice for 20min. The lysates (30ml)
were transferred to awhite 96-well plate together with 60ml of 1:8 diluted
YSi poly-D-lysine-coated beads (Perkin Elmer). After 10 min of vigorously
shaking and spinning (1,500 rpm, 5 min), the plate radioactivity was
counted on a top counter after 4 h to reach optimal measuring. De-
terminations were made in duplicates.
2.6. Mini Ga signaling in 3T3-L1 undifferentiated adipocytes
3T3-L1 cells were seeded in 96-well plates at a density of 9,000 cells/
well. After 24 h, the cells were transiently transfected with FFAR4-
NanoLuc and Venus ¼ tagged mini G protein probe isoform in a
1:10 ratio, respectively, using TransfeX (ATCC) transfection reagent
as per the manufacturer’s protocol. Mini G protein probes are modified
Ga subunits that recruit to active receptors in living cells. Here, they
were used to assess both the receptor activation and coupling spec-
ificity of the FFAR4 [32]. On the day of imaging, approximately 48 h
post-transfection, the FFAR4 antagonist AH7614 was applied to the
cells for 15 min at 10 mM. The cell medium was subsequently replaced
with HBSS containing furimazine/Nano-Glo Luciferase Assay Sub-
strate (Promega) at a final concentration of 10 mM of þ/ antagonist.
BRET measurements were then done at 37 C using a PHERAstar
plate reader at dual emission wavelengths using a BRET1 430e
485 nm and 505e590 nm dual filter optic module. Following four
baseline reads, agonist or vehicle was administered in triplicate for
each condition, and the BRET signal was measured every 2 min for 1 h.
The BRET ratio, acceptor 505e590 nm emission over 430e485 nm
donor emission, was calculated, and the baseline vehicle read was
subtracted from the agonist-stimulated read. The area under the curve
(AUC) was also calculated for ease of comparison.
2.7. In vivo lipolysis
Lean (30 1.8 g) and DIO (47.8 2 g) C57BL6/J mice were fasted for
17 h prior to the experiment. The mice were orally gavaged with either
30 mg/kg of CpdB, 30 mg/kg of nicotinic acid or vehicle control all
dissolved in 0.5% (w/v) carboxymethylcellulose sodium salt with
medium viscosity (SigmaeAldrich). Retroorbital blood (100 ml) was
collected from the mice prior to the administration and 30 min after
administration. NEFA was measured by a WAKO NEFA kit (WAKOMOLECULAR METABOLISM 42 (2020) 101103  2020 The Authors. Published by Elsevier GmbH. This is an open a
www.molecularmetabolism.comChemicals, Germany), and glycerol was measured by a SigmaeAldrich
total glycerol kit according to the protocols of the manufacturers.
2.8. Quantitative polymerase chain reaction (qPCR) analysis
Total RNA was extracted and purified from epididymal adipose tissue
isolated from lean or diet-induced obese (DIO) C57Bl6/J mice. Reverse
transcription PCR (RT-PCR) was performed using SuperScript III
Reverse Transcriptase (Invitrogen). Custom designed qPCR array
plates from Qiagen containing primers for FFAR4. CT values for the
target genes were normalized to the CT value of the ywhaz gene.
2.9. FFAR4KO mice studies
FFAR4KO and littermate control mice were fasted for 6 h, and an oral
glucose tolerance test (OGTT) was performed with 2 g/kg of glucose
administered by oral gavage and glucose levels measured in tail blood
at the different time points. Retro-orbital blood (200 ml) was collected
after the mice were fasted for 6 h and plasma was analyzed for insulin
content by MSD insulin plates (Meso Scale Discovery, USA), glycerol
was measured by a SigmaeAldrich total glycerol kit, and NEFA by the
WAKO NEFA kit (WAKO Chemicals, Germany) according to protocols
from the manufacturers.
2.10. Calculation and statistical analysis
Data were analyzed using Prism 7 software (GraphPad Software, San
Diego) using paired t-test, Student’s t-test, Tukey’s multiple com-
parison test, and two-way analysis of variance (ANOVA) as indicated in
the legend to each of the figures. Statistical significance is denoted by
* - (p < 0.05), ** - (p < 0.01), *** - (p < 0.001), and **** -
(p < 0.0001).
3. RESULTS
3.1. Endogenous ligands for FFAR4 are released in large amounts
from adipocytes
Conditioned media were collected from primary cultures of murine and
human adipocytes 30 min after induction of lipolysis by isoproterenol
or vehicle control. Concentrations of NEFAs were increased to 600 mM
in conditioned media from isoproterenol-stimulated adipocytes isolated
from epididymal fat depots of lean mice as compared to 100 mM in
media from vehicle-treated adipocytes (Figure 1A). LC-MS analysis of
the conditioned media demonstrated a strong increase in several types
of NEFAs, which from the literature are known to be ligands for FFAR4,
with linoleic acid, oleic acid, and palmitic acid as the main species
(Figure 1BeE and Table S2) [6]. Adipocytes isolated from subcu-
taneous, omental, and mesenteric adipose depots from obese patients
undergoing bariatric surgery all released known endogenous FFAR4
NEFA ligands in a similar pattern as the murine adipocytes, with the
expected difference that the basal levels were relatively high and the
isoproterenol-induced increase was relatively small compared to adi-
pocytes from lean mice (Figure 1 and Table S2).
3.2. Conditioned media from primary adipocytes activates FFAR4
signaling
Gq-mediated accumulation of inositol phosphate (IP) is a robust
readout of FFAR4 signaling demonstrated here by measuring IP
accumulation in COS-7 cells transiently transfected with the human
FFAR4. Three different potent and efficient, synthetic, non-lipid FFAR4
agonists, CpdA, CpdB, and AZ13581837 were selected as positive
controls, which stimulated IP accumulation 5.4e8.0-fold (Figure 2A).
Conditioned media from isoproterenol-stimulated murine adipocytes
stimulated IP accumulation in FFAR4-transfected cells 4.1-foldccess article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 3
Figure 1: Unstimulated and isoproterenol-induced (1 mM) release of NEFAs and specific LCFAs from primary adipocyte cultures obtained from murine (epididymal)
and human (subcutaneous, omental, and mesenteric) fat depots. Panel A - Total concentrations of NEFAs in conditioned media accumulated over 30 min. Panels B, C, and D
e Content of the three quantitatively dominating species of NEFAs: linoleic acid (Panel B), oleic acid (Panel C), and palmitoleic acid (Panel D) as well as docosahexaenoic acid (Panel
E) in conditioned media from the indicated fat depots before and after stimulation with isoproterenol as identified and quantified by LCMS analysis. Other species of NEFAs are
shown in Table S2. Data are presented as mean þ/ SEM for panel A. * - p < 0.05, ** - p < 0.01, *** - p < 0.001, **** - p < 0.0001 using paired t-test.
Brief Communication(Figure 2A) an effect, which was totally blocked by the selective
synthetic FFAR4 antagonist, AH7614 (Figure 2A). No effect of the
conditioned medium was observed in control, empty vector-
transfected COS-7 cells, and no effect was observed with un-
conditioned media (Figure 2A and S2). However, conditioned me-
dium from unstimulated murine adipocytes also induced IP4 MOLECULAR METABOLISM 42 (2020) 101103  2020 The Authors. Published by Elsevier GmbH. Taccumulation to a smaller degree, 1.8-fold, which was also FFAR4-
dependent as it was blocked by the FFAR4 antagonist (Figure 2A).
This ability of conditioned medium from nonstimulated adipocytes to
activate FFAR4 is in agreement with the observation that this me-
dium also contains NEFAs, albeit at much lower concentrations
(Figure 1).his is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 2: FFAR4/GPR120 signaling and activation by conditioned media from primary murine adipocyte cultures. Panel A e IP accumulation in COS-7 cells transiently
transfected with human FFAR4 (n ¼ 5). The cells were stimulated with conditioned media sampled from murine adipocytes with or without stimulation with isoproterenol and with
or without the specific, synthetic FFAR4 antagonist AH7614. The selective, synthetic FFAR4 agonists CpdA (1 mM), CpdB (1 mM), and AZ (1 mM) were used as positive controls.
Effects in empty vector control cells are shown in Fig. S2. Panel B e Setup for conditioned media stimulations of COS-7 cell in panel A. Panel C e Binding of different Ga subunits
to 1 mM of CpdA agonist stimulated FFAR4 as determined by BRET in undifferentiated 3T3-L1 cells transfected with FFAR4-NanoLuc alongside Venus-tagged mini G-proteins (Gaq,
Gai, Gao, Gas, and Ga12) with or without the FFAR4 antagonist AH7614 (n ¼ 3). Panel D and E e Effects of the specific synthetic FFAR4 agonist CpdA or HCAR2 agonist niacin on
isoproterenol induced cAMP accumulation in primary murine adipocytes in the absence (black curve) and the presence of IBMX (grey curve) (n ¼ 5). Data are presented as
mean þ/ SEM. * - p < 0.05, ** - p < 0.01, *** - p < 0.001, **** - p < 0.0001 using Tukey’s multiple comparison test for panel A, two-way ANOVA with multiple
comparison for panel B and Dunnet’s multiple comparison for panel C.3.3. FFAR4 signals strongly through Gi in undifferentiated 3T3-L1
cells
Although FFAR4 is considered to be a Gq-coupled receptor, it has also
been reported to signal through Gi in enteroendocrine cells, such as
ghrelin and somatostatin cells [11,33]. We therefore decided to studyMOLECULAR METABOLISM 42 (2020) 101103  2020 The Authors. Published by Elsevier GmbH. This is an open a
www.molecularmetabolism.comthe ability of FFAR4 to bind different types of G proteins in 3T3-L1 cells
transfected with mini-G proteins [32]. As shown in Figure 2C, the
prototypical FFAR4 agonist CpdA induced binding of mini-Gaq, which
was blocked by the FFAR4 antagonist AH7614. Importantly, however,
CpdA induced 3-fold higher activation of Gi subtypes, mini-Gai andccess article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 5
Figure 3: Effect of the FFAR4 specific agonist CpdB, the prototype anti-lipolytic agent nicotinic acid (niacin) on lipolysis in vivo in lean and DIO mice. Circulating NEFAs
in lean (Panel A) or diet-induced obese (DIO) mice (Panel B) fasted for 18 h and given either vehicle, niacin (30 mg/kg), or CpdB (30 mg/kg) by oral gavage as measured at time
zero and 30 min post gavage. Panel C - FFAR4 expression in subcutaneous, epididymal, or brown adipose tissues from lean (n ¼ 8) and DIO (n ¼ 10) mice. Data are presented as
mean þ/ SEM for panel C. * - p < 0.05, ** - p < 0.01, *** - p < 0.001, **** - p < 0.0001 using paired t-test for panel A and B and using Student’s t-test for panel C.
Brief Communicationmini-Gao (Figure 2C). In contrast, the binding of mini-Gas and mini-
Ga12 was negligible (Figure 2C).
3.4. Synthetic selective FFAR4 agonist decreases cAMP in
adipocytes
Isoproterenol, which is the canonical stimulator of lipolysis acting
through Gas and cAMP, dose-dependently increased cAMP accumu-
lation in primary cultures of murine adipocytes (Fig. S3). As shown in
Figure 2D, the synthetic, selective FFAR4 agonist, CpdA dose-
dependently inhibited the isoproterenol-induced cAMP accumulation.
For methodological reasons, i.e., to increase the signal, cells are often
treated with the phosphodiesterase inhibitor IBMX, which enhances the6 MOLECULAR METABOLISM 42 (2020) 101103  2020 The Authors. Published by Elsevier GmbH. Tisoproterenol-induced increase in cAMP. However, in IBMX treated
adipocytes the FFAR4 agonist did not inhibit the isoproterenol-
stimulated cAMP accumulation but instead a trend towards a slight,
increase was observed, with an at least 100-fold lower potency which
indicates that this may be an unspecific effect (Figure 2D). The lack of
an inhibitory effect of the synthetic FFAR4 in the IBMX-treated cells
may be due to saturation of the receptor by endogenously released
NEFA ligands in these massively activated cells. This notion is sup-
ported by the observation that the prototypic antilipolytic agent niacin,
which acts through another Gi-coupled receptor HCAR2 was still able
to inhibit the strong isoproterenol-induced increase in cAMP in the
IBMX-treated adipocytes (Figure 2E).his is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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3.5. FFAR4 activation inhibits lipolysis in lean but not obese mice
To test whether FFAR4 activation could inhibit lipolysis in vivo, we
tested the effect of an FFAR4 agonist in parallel with the well-known
antilipolytic agent niacin. Lean and DIO mice were fasted overnight
and gavaged orally with either vehicle, niacin (30 mg/kg), or the
synthetic, selective FFAR4 agonist CpdB (30 mg/kg). Both nicotinic
acid and CpdB decreased circulating levels of NEFA in all mice on
average by approximately 50% (Figure 3A). However, neither nicotinic
acid nor the FFAR4 agonist decreased NEFAs in DIO mice, which are
known to be relatively resistant to antilipolytic agents (Figure 4B) [21].
In fact, Ffar4 expression was decreased in WAT, particularly in
epididymal WAT as opposed to BAT from DIO mice as compared to lean
mice (Figure 3C).
3.6. Lipolysis is increased upon FFAR4 blockade and in FFAR4
deficient mice
Treatment of cultures of primary murine adipocytes with the specific
synthetic FFAR4 antagonist, AH7614 [28] increased isoproterenol-
induced cAMP accumulation by almost 50% (Figure 4A). This agrees
with the basic notion that the inhibitory, Gi-coupled FFAR4 receptor is
stimulated by NEFAs liberated through the isoproterenol-stimulated
lipolysis and that the FFAR4 antagonist works by blocking this auto-
crine inhibitory loop.
Finally, we focused on global FFAR4 KO mice. As reported in the
literature [20], FFAR4-deficient mice have slightly increased body
weight, are glucose intolerant (Fig. S4), and are slightly insulin-
resistant, which is associated with elevated insulin levels
(Figure 4B). Importantly, despite the elevated insulin levels, the FFAR4-
deficient mice had increased lipolysis as determined by the borderline
increased (p ¼ 0.054) circulating levels of NEFAs and highly signifi-
cantly elevated circulating glycerol (Figure 4B). Although several
mechanisms could be responsible for this evidence of increased
lipolysis, the data are at least in accordance with an inhibitory role of
FFAR4 on lipolysis observed in the WT littermate control animals,
which is absent in the FFAR4 KO animals.
4. DISCUSSION
This study presents evidence that FFAR4 is responsible for the auto-
crine inhibitory effect of NEFAs on lipolysis for which the molecularFigure 4: Stimulatory effect of FFAR4 blockade on cAMP accumulation in murine a
accumulation in primary murine adipocytes exposed to increasing concentrations of the
globally FFAR4-deficient mice, which also are glucose intolerant and moderately obese (see
mice (n ¼ 30). Data are presented as meanþ/- SEM. * - p < 0.05, ** - p < 0.01, *** - p
panels B and C.
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identified more than 40 years ago [1,2,4]. Our data indicates that
FFAR4 inhibits lipolysis by decreasing intracellular cAMP through Gi-
mediated inhibition of adenylyl cyclase (Figure 5).
4.1. FFAR4 as an autocrine sensor of NEFAs in WAT
Identification of palmitic acid, oleic acid, and linoleic acid as major
species of NEFAs released from adipocytes upon stimulation of lipol-
ysis fits well with previous reports in the literature [34e36]. Although
certain unsaturated fatty acids such as omega-3 fatty acids are slightly
more potent FFAR4 agonists, a broad range of saturated and unsat-
urated LCFAs, including the ones identified in the present study in
conditioned media from human and murine adipocytes, are in fact all
potent and efficacious FFAR4 agonists [6,37]. This implies that in the
cell membrane of adipocytes, FFAR4 will be exposed to a broad
spectrum of endogenous NEFAs and through its Gi coupling will inhibit
adenylate cyclase activity and lipolysis and thereby functions as a
sensor in a classical autocrine regulatory feedback loop (Figure 5). In
fact, the NEFAs may not have to actually leave the adipocyte to activate
FFAR4. In the closely related FFAR1 receptor, 2 binding sites for
synthetic LCFA mimetics have been identified, both of which are
exposed to the lipid bilayer, one for each leaflet of the bilayer [38].
Thus, LCFAs will likely access these sites by way of the lipid mem-
brane, in which they accumulate in high concentrations [39]. Although
the structure of FFAR4 remains to be characterized, it is likely that
FFAR4 is activated by NEFAs through a similar ‘intracrine’ molecular
mechanism.
The physiological role of FFAR4 in fine-tuning lipolysis and other
adipocyte functions through its role as a NEFA-sensing autocrine feed-
back regulator remains to be characterized in detail. The main problem
is that we do not yet have access to FFAR4 antagonists with appro-
priate bioavailability and ADME properties to be used as in vivo
pharmacological tools, and inducible, adipose-specific FFAR4 KO mice
strains are not yet available either. Nevertheless, one phenomenon for
which the Gi-coupled FFAR4 likely is responsible is the elusive, pro-
longed decrease in intracellular cAMP observed in adipocytes following
treatment with lipolytic agents [40,41]. Importantly, although the
present study focused on Gi signaling of FFAR4, FFAR4 can still
function also as a Gq-coupled receptor. However, despite the poorly
understood effects of Gq signaling in adipocytes, FFAR4 is likelydipocytes and of FFAR4 deficiency on lipolysis in vivo in mice. Panel A - cAMP
FFAR4-selective antagonist AH7614 (n ¼ 5). Panel B e Increased plasma insulin in
Fig. S4) (n ¼ 30). Panel C - Plasma levels of NEFAs and glycerol in globally FFAR4 KO
< 0.001, using Dunnett’s multiple comparison test for panel A and Student’s t-test for
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Figure 5: Simplified schematic overview of control of lipolysis by GPCRs with focus on FFAR4 in the context of the other putative autocrine feedback mechanisms.
The left side indicates the autocrine NEFA and FFAR4 and Gi-mediated autocrine negative feedback loop on lipolysis characterized in the present study, including the phar-
macological FFAR4 tool compounds used. The classical catecholamine, b1-receptor, Gs, and adenylate cyclase (AC)-mediated stimulatory control of lipolysis are indicated in
green. The right side indicates six different Gi-coupled metabolite sensing GPCRs, which all act as autocrine regulators of lipolysis and other adipocyte functions under different
physiological circumstances: The adenosine A1 receptor, which is responsible for the original, classical autocrine effects of adenosine [52]; the lactate receptor, HCAR1/GPR81,
which is responsible for the insulin, glucose-mediated inhibition of lipolysis [47]; the HCAR2/GPR109A receptor for circulating and possibly also locally produced b-hydroxybutyrate
and the prototype anti-lipolytic drug niacin [53]; the HCAR3/GPR109B receptor for b-hydroxyoctanoate [54]; the SUCNR1/GPR91 receptor sensing stress and hypoxia-induced
succinate excretion [39]; and FFAR2/GPR43, which senses acetate conceivably both through autocrine and paracrine mechanisms from certain subtypes of adipocytes [55].
Brief Communicationinvolved in glucose uptake as previously proposed by Olefsky [17] and
could also control gene expression.
4.2. Potential role of FFAR4 in adipocyte function in obesity and
diabetes
Obesity is generally associated with a high basal level of lipolysis and
decreased response to catecholamines as we also observed in the
present study (Figure 1). Although this so-called ‘catecholamine
resistance’ has been attributed to decreased expression of b-adren-
ergic receptors [42], we propose that FFAR4 could also be involved in
this phenomenon. The observation that FFAR4 is downregulated in
obesity in visceral as opposed to subcutaneous adipose tissue
(Figure 4) agrees with the fact that visceral adipose tissue of obese
individuals has a relatively higher rate of lipolysis compared to sub-
cutaneous fat [43,44].
4.3. Metabolite-mediated regulation of adipocyte function in
general
In addition to FFAR4, a number of other Gi-coupled metabolite re-
ceptors are expressed on adipocytes, most of which also function as
autocrine and/or paracrine sensors of adipocyte-generated metabolites
[5] (Figure 5). These receptors include the adenosine A1 receptor,
which is responsible for the inhibition of lipolysis associated with
autocrine sensing of adenosine described before the similar function of
NEFAs [45,46]. Through autocrine sensing of lactate, HCAR1/GPR81is
responsible for the major part of the canonical insulin-induced inhi-
bition of lipolysis [47]. The closely related HCAR2 or GPR109A sense
circulating and likely also locally produced beta-hydroxybutyrate; and
in humans, HCAR3/GPR109B senses beta-hydroxyoctanoate. SUCNR1/
GPR91 senses succinate generated in response to metabolic, hypoxic8 MOLECULAR METABOLISM 42 (2020) 101103  2020 The Authors. Published by Elsevier GmbH. Tstress and associated with reversal of succinate dehydrogenase.
Finally, in BAT, thermogenesis is regulated by FFAR2/GPR43 paracrine
sensing of acetate being excreted from a subpopulation of adipocytes
[55] (Figure 5). As indicated, each of these metabolite sensors function
under different physiological conditions to fine tune adipocyte function,
particularly lipolysis. In this respect, FFAR4 is special as its function is
directly coupled to lipolysis as it senses the product, NEFAs (Figure 5).
4.4. FFAR4 in BAT
In BAT, FFAR4 is highly upregulated upon cold exposure [3,16,22]. In
an unbiased screen, FFAR4 was even highlighted as one of the most
cold-induced genes in BAT [3]. As the increase in energy expenditure
upon cold exposure involves uptake and burning of fuel, FFAR4 may
serve a more sophisticated function in BAT than just inhibiting lipolysis.
For example, it may be speculated that FFAR4 signals back to block the
‘wasteful loss’ of NEFAs, which FFAR4 senses being released and
instead helps shunt the NEFAs to the burning machinery instead of out
of the cell. Here, FFAR4’s Gq signaling pathways could be important.
Importantly, it has been reported that FFAR4 activates not only
oxidative phosphorylation in BAT but also browning of WAT and that a
selective FFAR4 agonist, TUG-891, increases fuel uptake and fat
oxidation and reduces body weight and fat mass in mice [16,48].
4.5. FFAR4 as a potential drug target
FFAR4 agonists and dual FFAR4/FFAR1 agonists have been pursued as
potential drugs for the treatment of diabetes and obesity but have not
yet reached clinical development [6,37]. During preclinical develop-
ment it was - in accordance with the findings of the present study -
described by Satapati and coworkers that synthetic, non-metabolite
FFAR4 agonists have anti-lipolytic effects in vivo in mice [21]. In thehis is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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academic literature, FFAR4 agonism has been strongly advocated as
an anti-inflammatory mechanism for the treatment of diabetes and
obesity [17,23,49]. However, the direct anti-inflammatory effect of
FFAR4 agonists could unfortunately not be confirmed by the phar-
maceutical industry [21]. The fact that-first generation agonists for the
related FFAR1 were terminated in the late clinical phases due to liver
toxicity [50] and that second generation FFAR1 agonists were reported
to possess b-cell toxicity, might have dampened the enthusiasm for
FFAR4 agonists also. However, FFAR4 agonists should perhaps be
revisited as a novel means to treat diabetes, and in particular stea-
tohepatitis, because chronic treatment with the synthetic FFAR4
agonist CpdA clears the liver for fat in DIO mice [23]. This effect is likely
related to the FFAR4-mediated activation of thermogenic fat and the
associated increased fuel consumption [16,48,51]. Time will show
whether this beneficial fuel burning effect of FFAR4 agonists will carry
over to humans having less BAT; however, their ability to induce
browning of WAT and thereby the thermogenic fat capacity may be a
favorable indication [16,48].
4.6. Concluding remarks
The present study demonstrates that FFAR4 serves an important role
as a sensor of liberated NEFAs in adipocytes and thereby acts as a
feedback regulator of lipolysis but conceivably also other adipocyte
functions. The details of FFAR4’s different role in BAT and how its Gi
versus Gq and downstream signaling pathways are involved in this
remain unclear. However, it appears that FFAR4’s role as a drug target
is being revitalized with a new focus on thermogenic fat activation.
ACKNOWLEDGMENT
We thank Barbara Thaysen and Cecilie Fryland Appledorff for expert technical
assistance. The work was supported by Challenge Grant NNF140C0013655, Chal-
lenge Grant NNF15OC0016798, and Immunometabolism Grant NNF15CC0018346,
all from the Novo Nordisk Foundation (TWS) and The Novo Nordisk Foundation Center
for Basic Metabolic Research is supported by an unconditional grant
(NNF10CC1016515) from the Novo Nordisk Foundation to University of Copenhagen;
additional support for analytical development was obtained from the Carlsberg
Foundation (Semper Ardens to LOD). DC is supported by a Wellcome Trust Senior
Research Fellowship (212313/Z/18/Z).
CONFLICT OF INTEREST
No conflict of interest is reported
APPENDIX A. SUPPLEMENTARY DATA
Supplementary data to this article can be found online at https://doi.org/10.1016/j.
molmet.2020.101103.
REFERENCES
[1] Fain, J.N., Shepherd, R.E., 1975. Free fatty acids as feedback regulators of
adenylate cyclase and cyclic 3’:5’-AMP accumulation in rat fat cells. Journal of
Biological Chemistry 250(16):6586e6592.
[2] Burns, T.W., Langley, P.E., Terry, B.E., Robinson, G.A., 1978. The role of free
fatty acids in the regulation of lipolysis by human adipose tissue cells.
Metabolism 27(12):1755e1762.
[3] Kalderon, B., Azazmeh, N., Azulay, N., Vissler, N., Valitsky, M., Bar-Tana, J.,
2012. Suppression of adipose lipolysis by long-chain fatty acid analogs. The
Journal of Lipid Research 53(5):868e878.MOLECULAR METABOLISM 42 (2020) 101103  2020 The Authors. Published by Elsevier GmbH. This is an open a
www.molecularmetabolism.com[4] Jeanrenaud, B., Hepp, D., Renold, A.E., 1970. The influence of lipolysis on
energy metabolism of isolated fat cells. Hormone and Metabolic Research
2(Suppl 2):76e79.
[5] Husted, A.S., Trauelsen, M., Rudenko, O., Hjorth, S.A., Schwartz, T.W., 2017.
GPCR-mediated signaling of metabolites. Cell Metabolism 25(4):777e796.
[6] Ulven, T., Christiansen, E., 2015. Dietary fatty acids and their potential for
controlling metabolic diseases through activation of FFA4/GPR120. Annual
Review of Nutrition 35:239e263.
[7] Milligan, G., Shimpukade, B., Ulven, T., Hudson, B.D., 2017. Complex phar-
macology of free fatty acid receptors. Chemical Reviews 117(1):67e110.
[8] Edfalk, S., Steneberg, P., Edlund, H., 2008. Gpr40 is expressed in enter-
oendocrine cells and mediates free fatty acid stimulation of incretin secretion.
Diabetes 57(9):2280e2287.
[9] Itoh, Y., Kawamata, Y., Harada, M., Kobayashi, M., Fujii, R., Fukusumi, S.,
et al., 2003. Free fatty acids regulate insulin secretion from pancreatic beta
cells through GPR40. Nature 422(6928):173e176.
[10] Hauge, M., Ekberg, J.P., Engelstoft, M.S., Timshel, P., Madsen, A.N.,
Schwartz, T.W., 2017. Gq and Gs signaling acting in synergy to control GLP-1
secretion. Molecular and Cellular Endocrinology 449:64e73.
[11] Egerod, K.L., Engelstoft, M.S., Lund, M.L., Grunddal, K.V., Zhao, M., Barir-
Jensen, D., et al., 2015. Transcriptional and functional characterization of the
G protein-coupled receptor repertoire of gastric somatostatin cells. Endocri-
nology 156(11):3909e3923.
[12] Psichas, A., Larraufie, P.F., Goldspink, D.A., Gribble, F.M., Reimann, F., 2017.
Chylomicrons stimulate incretin secretion in mouse and human cells. Dia-
betologia 60(12):2475e2485.
[13] Ekberg, J.H., Hauge, M., Kristensen, L.V., Madsen, A.N., Engelstoft, M.S.,
Husted, A.S., et al., 2016. GPR119, a major enteroendocrine sensor of dietary
triglyceride metabolites coacting in synergy with FFA1 (GPR40). Endocrinology
157(12):4561e4569.
[14] Trauelsen, M., Luckmann, M., Frimurer, T.M., Schwartz, T.W., 2018. The HETE
is on FFAR1 and pancreatic islet cells. Cell Metabolism 27(2):273e275.
[15] Tunaru, S., Bonnavion, R., Brandenburger, I., Preussner, J., Thomas, D.,
Scholich, K., et al., 2018. 20-HETE promotes glucose-stimulated insulin
secretion in an autocrine manner through FFAR1. Nature Communications
9(1):177.
[16] Quesada-Lopez, T., Cereijo, R., Turatsinze, J.V., Planavila, A., Cairo, M.,
Gavalda-Navarro, A., et al., 2016. The lipid sensor GPR120 promotes brown fat
activation and FGF21 release from adipocytes. Nature Communications 7:
13479.
[17] Oh, D.Y., Talukdar, S., Bae, E.J., Imamura, T., Morinaga, H., Fan, W., et al.,
2010. GPR120 is an omega-3 fatty acid receptor mediating potent anti-
inflammatory and insulin-sensitizing effects. Cell 142(5):687e698.
[18] Gotoh, C., Hong, Y.H., Iga, T., Hishikawa, D., Suzuki, Y., Song, S.H., et al.,
2007. The regulation of adipogenesis through GPR120. Biochemical and
Biophysical Research Communications 354(2):591e597.
[19] Rodriguez-Pacheco, F., Garcia-Serrano, S., Garcia-Escobar, E., Gutierrez-
Repiso, C., Garcia-Arnes, J., Valdes, S., et al., 2014. Effects of obesity/fatty
acids on the expression of GPR120. Molecular Nutrition & Food Research
58(9):1852e1860.
[20] Ichimura, A., Hirasawa, A., Poulain-Godefroy, O., Bonnefond, A., Hara, T.,
Yengo, L., et al., 2012. Dysfunction of lipid sensor GPR120 leads to obesity in
both mouse and human. Nature 483(7389):350e354.
[21] Satapati, S., Qian, Y., Wu, M.S., Petrov, A., Dai, G., Wang, S.P., et al.,
2017. GPR120 suppresses adipose tissue lipolysis and synergizes with
GPR40 in antidiabetic efficacy. The Journal of Lipid Research 58(8):1561e
1578.
[22] Rosell, M., Kaforou, M., Frontini, A., Okolo, A., Chan, Y.W., Nikolopoulou, E.,
et al., 2014. Brown and white adipose tissues: intrinsic differences in gene
expression and response to cold exposure in mice. American Journal of
Physiology. Endocrinology and Metabolism 306(8):E945eE964.ccess article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 9
Brief Communication[23] Oh, D.Y., Walenta, E., Akiyama, T.E., Lagakos, W.S., Lackey, D.,
Pessentheiner, A.R., et al., 2014. A Gpr120-selective agonist improves insulin
resistance and chronic inflammation in obese mice. Nature Medicine 20(8):
942e947.
[24] Paerregaard, S.I., Agerholm, M., Serup, A.K., Ma, T., Kiens, B., Madsen, L.,
et al., 2016. FFAR4 (GPR120) signaling is not required for anti-inflammatory
and insulin-sensitizing effects of omega-3 fatty acids. Mediators of Inflam-
mation 2016:1536047.
[25] Bjursell, M., Xu, X., Admyre, T., Bottcher, G., Lundin, S., Nilsson, R., et al.,
2014. The beneficial effects of n-3 polyunsaturated fatty acids on diet induced
obesity and impaired glucose control do not require Gpr120. PloS One 9(12):
e114942.
[26] Sundstrom, L., Myhre, S., Sundqvist, M., Ahnmark, A., McCoull, W.,
Raubo, P., et al., 2017. The acute glucose lowering effect of specific
GPR120 activation in mice is mainly driven by glucagon-like peptide 1.
PloS One 12(12):e0189060.
[27] Watterson, K.R., Hansen, S.V.F., Hudson, B.D., Alvarez-Curto, E., Raihan, S.Z.,
Azevedo, C.M.G., et al., 2017. Probe-dependent negative allosteric modulators
of the long-chain free fatty acid receptor FFA4. Molecular Pharmacology 91(6):
630e641.
[28] Sparks, S.M., Chen, G., Collins, J.L., Danger, D., Dock, S.T., Jayawickreme, C.,
et al., 2014. Identification of diarylsulfonamides as agonists of the free fatty
acid receptor 4 (FFA4/GPR120). Bioorganic & Medicinal Chemistry Letters
24(14):3100e3103.
[29] Van Olden, C.C., Van de Laar, A.W., Meijnikman, A.S., Aydin, O., Van Olst, N.,
Hoozemans, J.B., et al., 2020. A Systems Biology approach to understand gut
microbiota and host metabolism in morbid obesity: design of the BARIA
Longitudinal Cohort Study. Journal of Internal Medicine.
[30] Fried, M., Yumuk, V., Oppert, J.M., Scopinaro, N., Torres, A., Weiner, R., et al.,
2014. Interdisciplinary European guidelines on metabolic and bariatric surgery.
Obesity Surgery 24(1):42e55.
[31] Barri, T., Holmer-Jensen, J., Hermansen, K., Dragsted, L.O., 2012. Metabolic
fingerprinting of high-fat plasma samples processed by centrifugation- and
filtration-based protein precipitation delineates significant differences in
metabolite information coverage. Analytica Chimica Acta 718:47e57.
[32] Wan, Q., Okashah, N., Inoue, A., Nehme, R., Carpenter, B., Tate, C.G., et al.,
2018. Mini G protein probes for active G protein-coupled receptors (GPCRs) in
live cells. Journal of Biological Chemistry 293(19):7466e7473.
[33] Engelstoft, M.S., Park, W.M., Sakata, I., Kristensen, L.V., Husted, A.S.,
Osborne-Lawrence, S., et al., 2013. Seven transmembrane G protein-coupled
receptor repertoire of gastric ghrelin cells. Molecular Metabolism 2(4):376e
392.
[34] Spitzer, J.J., Nakamura, H., Gold, M., Altschuler, H., Lieberson, M., 1966.
Correlation between release of individual free fatty acids and fatty acid
composition of adipose tissue. Proceedings of the Society for Experimental
Biology and Medicine 122(4):1276e1279.
[35] Conner, W.E., Lin, D.S., Colvis, C., 1996. Differential mobilization of fatty acids
from adipose tissue. The Journal of Lipid Research 37(2):290e298.
[36] Nakamura, H., Faludi, G., Spitzer, J.J., 1967. Changes of individual free fatty
acids during glucose tolerance test. Diabetes 16(3):175e180.
[37] Ichimura, A., Hasegawa, S., Kasubuchi, M., Kimura, I., 2014. Free fatty acid
receptors as therapeutic targets for the treatment of diabetes. Frontiers in
Pharmacology 5:236.
[38] Lu, J., Byrne, N., Wang, J., Bricogne, G., Brown, F.K., Chobanian, H.R., et al.,
2017. Structural basis for the cooperative allosteric activation of the free fatty
acid receptor GPR40. Nature Structural & Molecular Biology 24(7):570e577.10 MOLECULAR METABOLISM 42 (2020) 101103  2020 The Authors. Published by Elsevier GmbH. T[39] Luckmann, M., Trauelsen, M., Frimurer, T.M., Schwartz, T.W., 2020. Struc-
tural basis for GPCR signaling by small polar versus large lipid metabolites-
discovery of non-metabolite ligands. Current Opinion in Cell Biology 63:38e
48.
[40] Arner, P., 1976. Relationship between intracellular cyclic AMP and lipolysis in
human adipose tissue. Acta Medica Scandinavica 200(3):179e186.
[41] Sengupta, K., Long, K.J., Allen, D.O., 1981. Relationship among isoproterenol,
cyclic AMP, cyclic AMP-dependent protein kinase and lipolysis in perfused fat
cells. Journal of Pharmacology and Experimental Therapeutics 218(1):128e133.
[42] Collins, S., Daniel, K.W., Rohlfs, E.M., 1999. Depressed expression of
adipocyte beta-adrenergic receptors is a common feature of congenital and
diet-induced obesity in rodents. International Journal of Obesity and Related
Metabolic Disorders 23(7):669e677.
[43] Hellmer, J., Marcus, C., Sonnenfeld, T., Arner, P., 1992. Mechanisms for
differences in lipolysis between human subcutaneous and omental fat cells.
Journal of Clinical Endocrinology & Metabolism 75(1):15e20.
[44] Rebuffe-Scrive, M., Anderson, B., Olbe, L., Bjorntorp, P., 1990. Metabolism of
adipose tissue in intraabdominal depots in severely obese men and women.
Metabolism 39(10):1021e1025.
[45] Vannucci, S.J., Klim, C.M., Martin, L.F., LaNoue, K.F., 1989. A1-adenosine
receptor-mediated inhibition of adipocyte adenylate cyclase and lipolysis in
Zucker rats. American Journal of Physiology 257(6 Pt 1):E871eE878.
[46] Fredholm, B.B., Johansson, S., Wang, Y.Q., 2011. Adenosine and the regu-
lation of metabolism and body temperature. Advances in Pharmacology 61:
77e94.
[47] Ahmed, K., Tunaru, S., Tang, C., Muller, M., Gille, A., Sassmann, A., et al.,
2010. An autocrine lactate loop mediates insulin-dependent inhibition of
lipolysis through GPR81. Cell Metabolism 11(4):311e319.
[48] Schilperoort, M., van Dam, A.D., Hoeke, G., Shabalina, I.G., Okolo, A.,
Hanyaloglu, A.C., et al., 2018. The GPR120 agonist TUG-891 promotes
metabolic health by stimulating mitochondrial respiration in brown fat. EMBO
Molecular Medicine 10(3).
[49] Talukdar, S., Olefsky, J.M., Osborn, O., 2011. Targeting GPR120 and other
fatty acid-sensing GPCRs ameliorates insulin resistance and inflammatory
diseases. Trends in Pharmacological Sciences 32(9):543e550.
[50] Menon, V., Lincoff, A.M., Nicholls, S.J., Jasper, S., Wolski, K., McGuire, D.K.,
et al., 2018. Fasiglifam-induced liver injury in patients with type 2 diabetes:
results of a randomized controlled cardiovascular outcomes safety trial. Dia-
betes Care 41(12):2603e2609.
[51] Christian, M., 2020. Elucidation of the roles of brown and brite fat genes:
GPR120 is a modulator of brown adipose tissue function. Experimental
Physiology.
[52] Johansson, S.M., Lindgren, E., Yang, J.N., Herling, A.W., Fredholm, B.B.,
2008. Adenosine A1 receptors regulate lipolysis and lipogenesis in mouse
adipose tissue-interactions with insulin. European Journal of Pharmacology
597(1e3):92e101.
[53] Taggart, A.K., Kero, J., Gan, X., Cai, T.Q., Cheng, K., Ippolito, M., et al., 2005.
(D)-beta-Hydroxybutyrate inhibits adipocyte lipolysis via the nicotinic acid re-
ceptor PUMA-G. Journal of Biological Chemistry 280(29):26649e26652.
[54] Ahmed, K., Tunaru, S., Langhans, C.D., Hanson, J., Michalski, C.W., Kolker, S.,
et al., 2009. Deorphanization of GPR109B as a receptor for the beta-oxidation
intermediate 3-OH-octanoic acid and its role in the regulation of lipolysis.
Journal of Biological Chemistry 284(33):21928e21933.
[55] Sun, W., Dong, H., Balaz, M., Slyper, M., Drokhlyansky, E., Colleruori, G., et al.,
2020. Sn-RNA-Seq reveals an adipocyte subpupulation which regulates
thermogenesis. Nature. In Press.his is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
www.molecularmetabolism.com
